Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Large B-cell lymphoma: relapsing post-axi-cel

Sattva Neelapu • 7 Dec 2019
ASH 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Axicabtagene ciloleucel CAR-T

Sattva Neelapu, MD, Anderson Cancer Center, Houston, TX, outlines an analysis of large B-cell lymphoma patients who relapsed post-axi-cel. The loss of CD19 due to the downregulation and alternating splicing of the gene is believed to be responsible for relapse after treatment with this CAR. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Sattva Neelapu

0:42
Next steps with ADI-001
Sattva Neelapu • 5 Jun 2022
2:06
ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma
Sattva Neelapu • 5 Jun 2022
3:24
ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies
Sattva Neelapu • 5 Jun 2022
2:43
Long-term follow-up results of ZUMA-5: axi-cel in patients with R/R indolent NHL
Sattva Neelapu • 12 Dec 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals